INSYS (INSY) Syndros Should Have Solid Uptake - Piper Jaffray
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
Go back to INSYS (INSY) Syndros Should Have Solid Uptake - Piper Jaffray
July 5, 2016 8:45 AM EDT
RBC Capital analyst, Randall Stanicky, noted that this morning, INSYS Therapeutics (NASDAQ: INSY) announced that it has received approval for Syndros (Dronabinol OS), its cannabinoid dronabinol oral solution. The product will be used to treat AIDS-related anorexia and nausea and vomiting in patients receiving... More
July 5, 2016 6:56 AM EDT
Insys Therapeutics, Inc. (Nasdaq: INSY) announced that the U.S. Food and Drug Administration (FDA) has approved Insys dronabinol oral solution, Syndros, an orally administered liquid formulation of the pharmaceutical cannabinoid dronabinol, a pharmaceutical version of tetrahydrocannabinol ("THC"). Syndros is approved for use in treating anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. Syndros is currently awaiting scheduling by the U.S. Drug Enforcement Administration.
"We are very pleased... More
